Navigation Links
Dysfunctional chemokine receptor promotes candidiasis
Date:11/1/2013

Candida albicans is one of the leading causes of hospital-acquired infections in immune compromised patients. The risk of both developing candidiasis and the clinical outcome of infection is variable among patients, and the host-dependent factors that contribute to patient susceptibility to C. albicans infection are poorly understood. In this issue of the Journal of Clinical Investigation, Michail Lionakis and colleagues at the National Institute of Allergy and Infectious Diseases demonstrated that the chemokine receptor CX3CR1 is required for the interaction of C. albicans and macrophages in the kidney. Mice lacking this receptor were prone to C. albicans-induced kidney failure; however, these mice did not have increased fungal burden in other organs. Furthermore, the authors found that patients with a mutation in the gene encoding CX3CR1 were at higher risk of candidiasis. This study identifies an important role for the interaction of C. albicans and macrophages in disease progression and outcome.


'/>"/>

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related biology news :

1. Has modern science become dysfunctional?
2. Measuring progesterone receptor expression to improve hormone-receptor-positive cancer management
3. G protein-coupled receptor mediates the action of castor oil
4. BUSM study identifies receptors role in regulating obesity, type 2 diabetes
5. Cell receptor has proclivity for T helper 9 cells, airway inflammation
6. Steroid hormone receptor prefers working alone to shut off immune system genes
7. Jackson Laboratory researchers provide definitive proof for receptors role in synapse development
8. Dopamine-receptor gene variant linked to human longevity
9. How the tilt of a cell-surface receptor prevents cancer
10. Activation of cortical type 2 cannabinoid receptors ameliorates ischemic brain injury
11. Therapies for ALL and AML targeting MER receptor hold promise of more effect with less side-effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 15, 2019 , ... RCH ... Life Sciences and Healthcare companies, announces the availability of new specialty advisory practice, ... direction to start-up and emerging bio-pharma companies interested in achieving specific outcomes related ...
(Date:7/9/2019)... ... July 09, 2019 , ... Murrieta Genomics, a launch pad ... The founder and CEO of Tx Genetic, Helen Harrison, has spent several years ... epithelial connective tissue disorders. , “We are pleased and excited to join the ...
(Date:6/25/2019)... ... , ... ActX has launched a medical genetic interpretation ... can get access to professionally reviewed genetic screening similar to what a physician ... + Ancestry customers., With the ActX + 23andMe service, both 23andMe customers and ...
Breaking Biology News(10 mins):
(Date:7/11/2019)... LAS VEGAS (PRWEB) , ... July 11, 2019 , ... ... 2019, R3 provided complimentary regenerative therapies to eight military Veterans under the R3 Heroes ... procedures being complimentary. , The R3 Heroes Program allow anyone to nominate a military ...
(Date:7/9/2019)... ... July 08, 2019 , ... Balluff has been named a ... the 2019 Innovative Product of the Year which highlights cutting-edge advancements and achievements ... Sensors Expo & Conference 2019, held this week in San Jose, California. ...
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial impact ... to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... Over 142% increase in particle size , Over 3% alteration ...
(Date:6/18/2019)... ... 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived ... for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. The ... This IND is the first of several planned clinical trials which will enable ...
Breaking Biology Technology: